The development of CAR T cell therapy targeting B cell maturation antigen (BCMA) and other epitopes such as G-protein coupled receptor family C group 5 member D (GPRC5D) has drastically improved the ability to control advanced MM, but with a consequent risk of increasing infections. This evidence concerns the gene GPRC5D and infection.